Literature DB >> 33560913

CRISPR-Cas13 as an Antiviral Strategy for Coronavirus Disease 2019.

Yan Zhang1.   

Abstract

Entities:  

Year:  2020        PMID： 33560913     DOI： 10.1089/crispr.2020.29094.yzh

Source DB:  PubMed          Journal:  CRISPR J        ISSN： 2573-1599


× No keyword cloud information.
  4 in total

Review 1.  Engineering CRISPR/Cas13 System against RNA Viruses: From Diagnostics to Therapeutics.

Authors:  Yi Xue; Zhenzhen Chen; Wenxian Zhang; Jingjing Zhang
Journal:  Bioengineering (Basel)       Date:  2022-06-29

Review 2.  CRISPR-Cas system: from diagnostic tool to potential antiviral treatment.

Authors:  Aishwarya Rajan; Stuti Shrivastava; Akhilesh Kumar; Alok Kumar Singh; Pankaj Kumar Arora
Journal:  Appl Microbiol Biotechnol       Date:  2022-08-26       Impact factor: 5.560

Review 3.  Insights Gained from RNA Editing Targeted by the CRISPR-Cas13 Family.

Authors:  Li Liu; De-Sheng Pei
Journal:  Int J Mol Sci       Date:  2022-09-27       Impact factor: 6.208

4.  Methods for in vitro CRISPR/CasRx-Mediated RNA Editing.

Authors:  Yu-Fan Chuang; Peng-Yuan Wang; Satheesh Kumar; Suraj Lama; Fan-Li Lin; Guei-Sheung Liu
Journal:  Front Cell Dev Biol       Date:  2021-06-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.